NewLink Genetics Corporation (NASDAQ:NLNK) – Research analysts at SunTrust Banks lowered their Q3 2017 EPS estimates for shares of NewLink Genetics Corporation in a report released on Monday. SunTrust Banks analyst P. Lawson now expects that the biotechnology company will post earnings of ($0.75) per share for the quarter, down from their prior forecast of ($0.71). SunTrust Banks also issued estimates for NewLink Genetics Corporation’s Q4 2017 earnings at ($0.74) EPS and FY2017 earnings at ($2.78) EPS.
NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.21. The business had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 52.36% and a negative net margin of 161.94%. WARNING: This piece was originally reported by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://rinconhillneighbors.org/2017/08/13/q3-2017-eps-estimates-for-newlink-genetics-corporation-reduced-by-analyst-nasdaqnlnk-updated.html.
A number of other research firms also recently weighed in on NLNK. Zacks Investment Research downgraded shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, April 4th. Stifel Nicolaus restated a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a report on Thursday, April 6th. Jefferies Group LLC raised their price target on shares of NewLink Genetics Corporation from $15.00 to $18.00 and gave the company a “hold” rating in a report on Thursday, April 6th. Cantor Fitzgerald restated an “overweight” rating and set a $32.00 price target (up previously from $20.00) on shares of NewLink Genetics Corporation in a report on Saturday, April 22nd. Finally, ValuEngine upgraded shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Friday, May 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $18.17.
Shares of NewLink Genetics Corporation (NASDAQ NLNK) opened at 7.40 on Wednesday. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17. The stock’s 50 day moving average price is $7.20 and its 200-day moving average price is $13.88. The firm’s market capitalization is $216.68 million.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in NewLink Genetics Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after buying an additional 51,013 shares in the last quarter. FMR LLC increased its position in NewLink Genetics Corporation by 119.3% in the fourth quarter. FMR LLC now owns 904,856 shares of the biotechnology company’s stock worth $9,302,000 after buying an additional 492,330 shares in the last quarter. State Street Corp increased its position in NewLink Genetics Corporation by 5.7% in the fourth quarter. State Street Corp now owns 430,428 shares of the biotechnology company’s stock worth $4,422,000 after buying an additional 23,029 shares in the last quarter. Columbus Circle Investors increased its position in NewLink Genetics Corporation by 155.6% in the first quarter. Columbus Circle Investors now owns 343,041 shares of the biotechnology company’s stock worth $8,267,000 after buying an additional 208,816 shares in the last quarter. Finally, Driehaus Capital Management LLC acquired a new position in NewLink Genetics Corporation during the first quarter worth $5,127,000. Institutional investors and hedge funds own 51.25% of the company’s stock.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with our FREE daily email newsletter.